About InGen
InGen is a company based in Chilly-mazarin (France) founded in 1993 was acquired by Diaxonhit in November 2012. InGen operates in a competitive market with competitors including Horizon Discovery, Quanterix, Arrakis Therapeutics, NanoString and Souzhou Ribo Life Science, among others.
- Headquarter Chilly-mazarin, France
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of InGen
Detailed funding history for InGen
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in InGen
InGen has secured backing from 1 investor. Prominent investors backing the company include Diaxonhit.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Fully integrated in vitro diagnostics company specializing in transplantation, infectious diseases and cancer diagnosis
|
Locked | Locked | Locked |
Investor details for InGen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by InGen
Investment portfolio details for InGen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - InGen
Detailed financials for InGen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ingen Comparisons
Peer comparison for InGen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of InGen
InGen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Horizon Discovery, Quanterix, Arrakis Therapeutics, NanoString and Souzhou Ribo Life Science, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genetically modified cell lines are developed using AAV gene-editing platform.
|
|
| Locked | Locked | Locked |
Assay kits for ultra-sensitive biomarker detection are developed.
|
|
| Locked | Locked | Locked |
Provider of tools for the analysis of RNA structures
|
|
| Locked | Locked | Locked |
Tools for translational research and molecular diagnosis are developed.
|
|
| Locked | Locked | Locked |
Nucleic acid drugs are developed via RNA interference technology.
|
|
| Locked | Locked | Locked |
Molecular biology reagents and services are supplied to biotech industries.
|
Detailed competitors of InGen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ingen
Complete news archive for InGen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about InGen
InGen was founded in 1993.
InGen is headquartered in Chilly-mazarin, France. It is registered at Chilly-mazarin, Ile-de-france, France.
InGen is engaged in the development, manufacture and marketing of in-vitro diagnostic products for clinical laboratory market. The company offers a range of ELISA kits, Rapid Diagnostic Tests (RDT), Immunodots, Immunofluorescence and Luminex for detection in the fields of infectious diseases and autoimmunity. The diagnostic tests are available for the area of Bacteriology (Respiratory infections, STDs, test for Staphylococcus (Luminex), Helicobacter pylori (ELISA), Lyme and tests for determining vaccination status for pertussis, diphtheria, and tetanus), Virology, Parasitology, Mycology, Auto-immune diseases, reagents for Complement analyses, and Hormonology. In partnership with ONE LAMBDA and CYLEX companies, company offers diagnostic tools for assessing donor-recipient matching (DNA-typing for HLA, KIR and Mica alleles, the detection and identification of anti-HLA antibodies) as well as a personalized monitoring of transplanted patients. In addition, it offers a wide range of tests for detection of PCR (Reaction Polymerase Chain) translocations, clonal rearrangements, and mutations in genes for the detection of leukemia and lymphoma. The company was acquired in 2006 by the biotechnology company IBS (ex AbAg). In 2012, Exonhit bought InGen for 23.1M, and created a new company called Diaxonhit.
InGen's top competitors include Horizon Discovery, NanoString and Quanterix.
InGen has 1 investor. Key investors include Diaxonhit.